NCT06464458View on ClinicalTrials.gov

Optimizing the Management of Sickle Cell Patients on Hydroxyurea: The Value of Therapeutic Pharmacological Monitoring

NARecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

August 7, 2025

Study Completion Date

August 7, 2025

Conditions
Sickle Cell Disease
Interventions
OTHER

management on hydroxyurea by therapeutic pharmacological monitoring

"HU dose adaptation according:~* HU AUC with a target AUC and subject to haematological tolerance.~* T2H (at V2, V3, V4), subject to haematological tolerance."

Trial Locations (1)

67091

RECRUITING

Strasbourg University Hospital, Strasbourg

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER